Targeting specific genes to improve treatment for head and neck cancer
Synthetic Lethal Targeting of CREBBP/EP300 in Head and Neck Squamous Cell Carcinoma
['FUNDING_R01'] · YALE UNIVERSITY · NIH-10804966
This study is looking at how changes in certain genes might help make current cancer treatments work better for people with head and neck cancer, so they can get more effective care.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | YALE UNIVERSITY (nih funded) |
| Locations | 1 site (NEW HAVEN, UNITED STATES) |
| Trial ID | NIH-10804966 on ClinicalTrials.gov |
What this research studies
This research investigates how targeting the CREBBP and EP300 genes can enhance the effectiveness of existing DNA-damaging treatments for head and neck squamous cell carcinoma (HNSCC). By using advanced genomic techniques, the study aims to identify how mutations in these genes can make cancer cells more sensitive to therapies like radiation and chemotherapy. The approach involves testing these gene targets in laboratory settings to understand their role in cell death and treatment response. If successful, this could lead to more effective treatment strategies for patients with HNSCC.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with head and neck squamous cell carcinoma, particularly those with mutations in the CREBBP or EP300 genes.
Not a fit: Patients with head and neck cancers that do not involve mutations in the CREBBP or EP300 genes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment outcomes for patients with head and neck cancer by making existing therapies more effective.
How similar studies have performed: Other research has shown promising results in targeting similar genetic pathways to enhance cancer treatment, indicating that this approach may be viable.
Where this research is happening
NEW HAVEN, UNITED STATES
- YALE UNIVERSITY — NEW HAVEN, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PICKERING, CURTIS — YALE UNIVERSITY
- Study coordinator: PICKERING, CURTIS
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.